Among these, ER-negative and triple-negative breast cancers (ER-/PR-/HER2-negative) are types of aggressive tumours that account for approximately 30% and 15% of breast cancers, respectively [2] and are known to have a poorer prognosis than most ER-positive types. This evidence concerns the gene ERBB2 and neoplasm.